Rapid cellular clearance severely restricts the effective analytical and functional windows of intracellular probes. Herein, we developed an endogenous enzyme-driven adaptive DNA nanomachine (TRZL) that synchronizes target recognition with in situ morphological transformation to overcome premature cellular clearance for prolonged intracellular theranostics. Specifically, a spatially confined hybridization chain reaction (HCR) circuit and an apurinic/apyrimidinic endonuclease 1 (APE1)-responsive module, which initially locks a DNAzyme, are integrated onto a rigid DNA prism framework. In tumor cells, APE1 recognition triggers the HCR circuit accompanied by fluorescence recovery, enabling sensitive APE1 detection with an ultralow limit of detection (LOD) of 9.60 × 10−4 U/mL. Concurrently, the continuous extension of the HCR polymers drives an in situ hydrodynamic size expansion from 37 nm monomers into 479 nm 3-dimensional networks. The resulting steric hindrance effectively mitigates rapid cellular clearance, successfully extending the signal retention window by maintaining 85.34% of the APE1-triggered signal over 24 h. Furthermore, benefiting from this aggregation-driven retention, the synchronously released DNAzyme can continuously cleave survivin mRNA to achieve sustained protein downregulation, thereby extending the functional window. Ultimately, this programmable size-adaptive strategy provides a highly versatile theranostic platform for precise bioanalysis and long-acting intervention.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: